Ariel Cohen, Ph.D. is a Senior Fellow at the Atlantic Council and the Founding Principal of International Market Analysis, a Washington, D.C.-based global risk advisory boutique. He is also ...
Our research team assigns Neutral ratings to strategies they’re not confident will outperform a relevant index, or most peers, over a market cycle on a risk-adjusted basis. Managers John Rogers ...
This strategy and its sibling, Ariel Fund ARGFX, use a similar contrarian process and have significant overlap in their holdings, but this strategy tends to invest in slightly larger-cap companies.
Ariel Plasencia joined FOX 13 in April 2023 and is excited to be reporting in the Sunshine State. Ariel spent the last four years in Dallas, TX covering news, sports (yes, including the Cowboys), and ...
It has been around a year since Beam Therapeutics slashed its headcount and R&D programmes to focus mainly on a sickle cell disease candidate – and the biotech has now revealed the first data ...
Bernstein has upgraded Beam Therapeutics (NASDAQ:BEAM) to outperform from market perform, citing upcoming data on the company’s drug candidate for alpha-1 antitrypsin deficiency, or AATD.